Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn:
“Among patients with triple-negative breast cancer (TNBC), does the presence of HER2-low expression make any difference in prognosis?
Studies to date have been inconclusive. We’re progressively learning why.
In our latest study, with central re-analysis of samples from 196 patients with mTNBC, we report a significant association between androgen receptor (AR) expression and HER2-low expression, highlighting a potential confounder of prognostic analyses and a potential therapeutic target enriched in HER2-low tumors.”
Title: Androgen Receptor Expression and Immune Characteristics of HER2-Low Metastatic Triple-Negative Breast Cancer
Authors: Paolo Tarantino, Jaeyoon Cha, Busem Binboga Kurt, Xiangying Chu, Bojana Jovanović, Andrew Zhou, Melissa Hughes, Douglas Russo, Molly DiLullo, Eileen Wrabel, Rinath Jeselsohn, Nancy U. Lin, Jamie Carter, Yisang Serenity Chen, Tianyu Li, Nabihah Tayob, Elizabeth A. Mittendorf, Stuart J. Schnitt, Shom Goel and Sara M. Tolaney.
Other articles featuring Paolo Tarantino on OncoDaily.